CD274 and neoplasm: PD-1/PD-L1 inhibitors, such as pembrolizumab, nivolumab, and dostarlimab, block the immune checkpoint interaction between PD-1 on T cells and PD-L1 on tumor cells, restoring T-cell activity and enabling anti-tumor immune responses.